Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer, adenocarcinoma of esophagogastric junction, Gastric adenocarcinoma patients.
Esophageal Squamous Cell Cancer, Adenocarcinoma of Esophagogastric Junction, Gastric Adenocarcinoma
DRUG: Tucidinostat (chidamide), PD-1 inhibitor (Toripalimab), Bevacizumab
Objective Response Rate（ORR）, Objective Response Rate（ORR）by RECIST 1.1,the total proportion of patients with complete response（CR）, partial response（PR）, 2 years
Progression-free survival(PFS), Time from treatment until disease progression or death, 2 years|Disease Control Rate （DCR）, the total proportion of patients with complete response（CR）, partial response（PR）and stable disease（SD）, 2 years|Duration of Response（DoR）, Time from the achievement of a response to progression, 2 years|Overall survival(OS), Time from treatment until death from any cause, 3 years
This Phase II study was designed to assess the efficacy and safety of the combination of PD-1 inhibitor, Tucidinostat (chidamide), a histone deacetylase inhibitor, and bevacizumab in advanced Esophageal squamous cell cancer, adenocarcinoma of esophagogastric junction, Gastric adenocarcinoma patients.